Selected studies of daunorubicin in adult acute nonlymphocytic leukemia.

[1]  R. O'reilly.  Allogenic bone marrow transplantation: current status and future directions. , 1983, Blood.

[2]  C. Schiffer,et al.  Evaluation of levamisole as an adjuvant to chemotherapy for treatment of ANLL , 1983, Cancer.

[3]  N. Nissen,et al.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.

[4]  C. Bloomfield,et al.  Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. , 1981, Blood.

[5]  C. Spurr,et al.  A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. , 1979, Medical and pediatric oncology.

[6]  J. Smyth,et al.  The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemia. , 1976, European journal of cancer.

[7]  M. Boiron,et al.  Daunorubicin in the therapy of acute granulocytic leukemia. , 1973, Cancer research.

[8]  R. Benjamin,et al.  High‐dose daunorubicin therapy for acute nonlymphocytic leukemia: Correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity , 1972, Cancer.

[9]  P. Wiernik,et al.  A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia. , 1972, Cancer research.

[10]  M. Boiron,et al.  Daunorubicin in the treatment of acute myelocytic leukaemia. , 1969, Lancet.